Identification of three highly attenuated Salmonella typhimurium mutants that are more immunogenic and protective in mice than a prototypical aroA mutant

Infection and Immunity

Volumn 66, Issue 7, 1998, Pages 3378-3383

  Valentine, Peter J ^a   Devore, Brian P ^a   Heffron, Fred ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SALMONELLOSIS VACCINE;

ANIMAL MODEL; ARTICLE; BACTERIUM IDENTIFICATION; CONTROLLED STUDY; IMMUNE RESPONSE; IMMUNOGENICITY; MICROBIAL ATTENUATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SALMONELLA TYPHIMURIUM; SALMONELLOSIS;

EID: 0031844796     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.66.7.3378-3383.1998     Document Type: Article

References (38)

1. Baumler, A. J., J. G. Kusters, I. Stojiljkovic, and F. Heffron. 1994. Salmonella typhimurium loci involved in survival within macrophages. Infect. Immun. 62:1623-1630.
2. Blattner, F. R., G. R. Plunkett, C. A. Bloch, N. T. Perna, V. Burland, M. Riley, J. Collado-Vides, J. D. Glasner, C. K. Rode, G. F. Mayhew, J. Gregor, N. W. Davis, H. A. Kirkpatrick, M. A. Goeden, D. J. Rose, B. Mau, and Y. Shao. 1997. The complete genome sequence of Escherichia coli K-12. Science 277:1453-1462.
3. Bowe, F., C. J. Lipps, R. M. Tsolis, E. Groisman, F. Heffron, and J. G. Kusters. 1998. At least four percent of the Salmonella typhimurium genome is required for fatal infection of mice. Infect. Immun. 66:3372-3377.
4. Burland, V., G. R. Plunkett, H. J. Sofia, D. L. Daniels, and F. R. Blattner. 1995. Analysis of the Escherichia coli genome VI: DNA sequence of the region from 92.8 through 100 minutes. Nucleic Acids Res. 23:2105-2119.
5. Chatfield, S. N., K. Strahan, D. Pickard, I. G. Charles, C. E. Hormaeche, and G. Dougan. 1992. Evaluation of Salmonella typhimurium strains harbouring defined mutations in htrA and aroA in the murine salmonellosis model. Microb. Pathog. 12:145-151.
6. Curtiss, R., III, and S. M. Kelly. 1987. Salmonella typhimurium deletion mutants lacking adenylate cyclase and cyclic AMP receptor protein are avirulent and immunogenic. Infect. Immun. 55:3035-3043.
7. Curtiss, R., III, S. M. Kelly, S. A. Tinge, C. O. Tacket, M. M. Levine, J. Srinivasan, and M. Koopman. 1994. Recombinant Salmonella vectors in vaccine development. Dev. Biol. Stand. 82:23-33.
8. Dorman, C. J., S. Chatfield, C. F. Higgins, C. Hayward, and G. Dougan. 1989. Characterization of porin and ompR mutants of a virulent strain of Salmonella typhimurium: ompR mutants are attenuated in vivo. Infect. Immun. 57:2136-2140.
9. Dougan, G., S. N. Chatfield, D. Pickard, D. O'Callaghan, and D. Maskell. 1988. Construction and characterisation of Salmonella vaccine strains harbouring mutations in two different aro genes. J. Infect. Dis. 158:1329-1335.
10. Eisen, H. N. 1990. General immunology, 2nd ed. J. B. Lippincott Co., Philadelphia, Pa.
11. Everest, P., P. Griffiths, and G. Dougan. 1995. Live Salmonella vaccines as a route towards oral immunisations. Biologicals 23:119-124.
12. Fields, P. I., R. V. Swanson, C. G. Heidaris, and F. Heffron. 1986. Mutants of Salmonella typhimurium that cannot survive inside macrophages are avirulent. Proc. Natl. Acad. Sci. USA 83:5189-5193.
13. Finlay, B. B., and S. Falkow. 1989. Common themes in microbial pathogenicity. Microbiol. Rev. 53:210-230.
14. Finlay, B. B., M. N. Starnbach, C. Francis, B. A. D. Stocker, S. N. Chatfield, G. Dougan, and S. Falkow. 1988. Identification and characterization of TnphoA mutants of Salmonella which are unable to penetrate through a polarized MDCK epithelial cell monolayer. Mol. Microbiol. 2:757-766.
15. Fognini-Lefebvre, N., J. C. Lazzaroni, and R. Portalier. 1987. tolA, tolB and excC, three cistrons involved in the control of pleiotropic release of periplasmic proteins by Escherichia coli K12. Mol. Gen. Genet. 209:391-395.
16. Galan, J. E., and R. Curtiss III. 1989. Virulence and vaccine potential of phoP mutants of Salmonella typhimurium. Microb. Pathog. 6:433-443.
17. Germanier, R., and E. Fuer. 1975. Isolation and characterization of a galE mutant Ty21a of Salmonella typhi: a candidate strain for a live oral typhoid vaccine. J. Infect. Dis. 131:553-558.
18. Groisman, E. A., C. Parra-Lopez, M. Salcedo, C. J. Lipps, and F. Heffron. 1992. Resistance to host antimicrobial peptides is necessary for Salmonella virulence. Proc. Natl. Acad. Sci. USA 89:11939-11943.
19. Hensel, M., J. E. Shea, C. Gleeson, M. D. Jones, E. Dalton, and D. W. Holden. 1995. Simultaneous identification of bacterial virulence genes by negative selection. Science 269:400-403.
20. Hohmann, E. L., C. A. Oletta, K. P. Killeen, and S. I. Miller. 1996. phoP/ phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers. J. Infect. Dis. 173:1408-1414.
21. Hohmann, E. L., C. A. Oletta, and S. I. Miller. 1995. Evaluation of a phoP/phoQ-deleted, aroA-deleted live oral Salmonella typhi vaccine strain in human volunteers. Vaccine 14:19-24.
22. Hone, D. M., A. M. Harris, S. Chatfield, G. Dougan, and M. M. Levine. 1991. Construction of genetically defined double aro mutants of Salmonella typhi. Vaccine 9:810-816.
23. Karem, K. L., S. Chatfield, N. Kuklin, and B. T. Rouse. 1995. Differential induction of carrier antigen-specific immunity by Salmonella typhimurium live-vaccine strains after single mucosal or intravenous immunization of BALB/c mice. Infect. Immun. 63:4557-4563.
24. Leung, K. Y., and B. B. Finlay. 1991. Intracellular replication is essential for the virulence of Salmonella typhimurium. Proc. Natl. Acad. Sci. USA 88: 11470-11474.
25. Levine, M. M., C. Ferriccio, R. E. Black, and R. Germanier. 1987. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric coated capsule formulation. Lancet i:1049-1052.
26. Levine, M. M., D. Hone, C. Tacket, C. Ferreccio, and S. Cryz. 1990. Clinical and field trials with attenuated Salmonella typhi as live oral vaccines and as "carrier" vaccines. Res. Microbiol. 141:807-816.
27. Mahan, M. J., J. M. Slauch, and J. J. Mekalanos. 1993. Selection of bacterial virulence genes that are specifically induced in host tissues. Science 259:686-688.
28. Miller, S. I., J. J. Mekalanos, and W. S. Pulkkinen. 1990. Salmonella vaccines with mutations in the phoP virulence regulon. Res. Microbiol. 141: 817-821.
29. O'Callaghan, D., D. Maskell, F. Y. Liew, C. S. F. Easmon, and G. Dougan. 1988. Characterization of aromatic- and purine-dependent Salmonella typhimurium: attenuation, persistence, and ability to induce protective immunity in BALB/c mice. Infect. Immun. 56:419-423.
30. Reed, L. J., and H. Muench. 1938. A simple method for estimating fifty percent endpoints. Am. J. Hyg. 27:493-497.
31. Schodel, F., and R. Curtiss III. 1995. Salmonellae as oral vaccine carriers. Dev. Biol. Stand. 84:245-253.
32. Sigwart, D. F., B. A. D. Stocker, and J. D. Clements. 1989. Effect of a purA mutation on efficacy of Salmonella live-vaccine vectors. Infect. Immun. 57: 1858-1861.
33. Staats, H. F., R. J. Jackson, M. Marinaro, I. Takahashi, H. Kiyono, and J. R. McGhee. 1994. Mucosal immunity to infection with implications for vaccine development. Curr. Opin. Immunol. 6:572-583.
34. Tacket, C. O., D. M. Hone, R. Curtiss III, S. M. Kelly, G. Losonsky, L. Guers, A. M. Harris, R. Edelman, and M. M. Levine. 1992. Comparison of the safety and immunogenicity of ΔaroC ΔaroD and ΔcyaΔcrp Salmonella typhi strains in adult volunteers. Infect. Immun. 60:536-541.
35. Tacket, C. O., D. M. Hone, G. A. Losonsky, L. Guers, R. Edelman, and M. M. Levine. 1992. Clinical acceptability and immunogenicity of CVD908 Salmonella typhi vaccine strain. Vaccine 10:443-446.
36. Tacket, C. O., M. B. Sztein, G. A. Losonsky, S. S. Wasserman, J. P. Nataro, R. Edelman, D. Pickard, G. Dougan, S. N. Chatfield, and M. M. Levine. 1997. Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans. Infect. Immun. 65:452-456.
37. Valentine, P. J., K. Meyers, M. M. Rivera, C. Lipps, D. Pauza, R. T. Maziarz, M. So, and F. Heffron. 1996. Induction of SIV capsid-specific CTL and mucosal sIgA in mice immunized with a recombinant S. typhimurium aroA mutant. Vaccine 14:138-146.
38. Yamamoto, Y., H. Aiba, T. Baba, K. Hayashi, T. Inada, K. Isono, T. Itoh, S. Kimura, M. Kitagawa, K. Makino, T. Miki, N. Mitsuhashi, K. Misobuchi, H. Mori, S. Nakade, Y. Nakamura, H. Hashimoto, T. Oshima, S. Oyama, N. Saito, G. Sampei, Y. Satoh, S. Sivasundaram, H. Tagami, T. Horiuchi, et al. 1997. Construction of a contiguous 874-kb sequence of the Escherichia coli K-12 genome corresponding to 50.0-68.8 min on the linkage map and analysis of its sequence features. DNA Res. 4:91-113.